- Abbott gets rights to Reata's Phase II bardoxolone
- Third Rock puts $40mm into Blueprint Medicines’ Series A
- Daiichi buys Plexxikon for $805mm up front, plus earn-outs
- Bayer Schering Pharma, OncoMed ally in cancer stem cells
- Vertex picks up global rights to two HCV candidates from Alios; Vertex ends HCV program
- Forma gives Genentech option to buy cancer candidate
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.